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Pertussis is a highly contagious respiratory tract disease caused 
by Bordetella pertussis infection. The clinical manifestation of this 
infection can be severe enough to cause death. Although pertussis 
has been  supposed to be a vaccine-preventable disease ever 
since the widespread vaccination of children against pertussis was 
started, since the 1990s, cases of pertussis and related fatalities are 
on the rise, especially in countries with high vaccination coverage. 
In Korea, there have been no deaths due to pertussis since 1990, 
and the vaccination rate continues to be approximately 94%. 
However, the number of pertussis cases reported to the Korea 
Center for Disease Control and Prevention has tended to increase 
in the 2000s, and in 2009, there was an obvious increase in the 
number of pertussis cases reported. This review aims to present the 
latest information about the pathogenesis, diagnosis, treatment, and 
prevention of pertussis. 
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Introduction
Pertussis is an acute respiratory tract infection caused by 
Bordetella pertussis; this infection is most severe in infants. 
Pertussis was a major cause of infant death before the introduction 
of vaccination. There are still 60 million cases of pertussis each year 
worldwide, resulting in about 300,000 deaths
1). Most of the deaths 
have been of unvaccinated children from developing countries. 
However, pertussis cases are increasing in Western countries with 
high vaccination coverage since the 1990s
2). In Korea, an average 
of approximately 11.5 cases of pertussis is reported to the Korea 
Center for Disease Control and Prevention (KCDC) each year, 
and there have been no fatalities since the 1990s
3). However, in 
the 2000s, the pertussis cases reported tended to increase, with 
up to 66 cases being reported in 2009
4, 5). Since the diagnosis of 
the reported cases was confirmed by PCR and culture without 
serology, the actual number of cases must be much more than 66 
in 2009. This trend of increasing pertussis cases is now becoming 
obvious in Korea. This article was intended to review the latest 
knowledge about the pathogenesis, epidemiology, diagnosis, 
treatment, and prevention of pertussis.
Pathogenesis  
Pertussis is a mucosal infection whose pathogenesis is induced by 
the local and systemic effects of toxins.
More than 95% of pertussis cases occur during epidemics and 
in endemic areas and are caused by B. pertussis infection; the 
remaining 5% of cases are caused by infection with Bordetella 
parapertussis
6). B. pertussis is the only gram-negative coccobacillus, 
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and Bordetella spp. possess the pertussis toxin (PT), which is 
the bacteria’s major virulence protein that infects only humans. 
B. pertussis organisms are acquired through aerosols and have 
strict tropism for the ciliated epithelium of the respiratory 
tract. Attachment to target cells is mediated by filamentous 
hemagglutinin (FHA), some agglutinogens (especially FIM2 
and FIM3), a 69-kd nonfimbrial surface protein called pertactin 
(PRN), and PT. Bacterial survival is aided by ciliostasis related to 
the tracheal cytotoxin (TCT) and impaired leukocyte function 
due to PT and the adenylate cyclase (AC) toxin. Local epithelial 
damage and respiratory tract symptomatology are mediated by 
the TCT and AC toxins. PT plays a major role in the severity of 
pertussis cough, encephalopathy, and lymphocytosis by preventing 
migration of the organism from the circulating blood
7).
Epidemiology 
Pertussis is highly contagious, with attack rates as high as 100% 
in susceptible individuals who have been exposed to contaminated 
aerosol droplets at close range. Natural disease and vaccination 
elicit broad antibody and cell-mediated immune responses. 
However, neither the disease nor vaccination confer complete or 
lifelong immunity against the disease or protect against reinfection. 
Protection against the typical disease begins to wane 3 to 5 years 
after vaccination and is not measurable by 12 years. When exposed 
to pertussis infection, over 50% of vaccinated people develop 
asymptomatic, mild desease
8) and become a source of infection for 
infants in whom pertussis may result in hospitalization and death. 
Pertussis is a significant cause of mortality in early infancy 
worldwide, despite widespread vaccination. It remains endemic 
in many industrialized countries, which have reported increases 
in incidence during the past several decades. This increase has 
been mainly among adults and adolescents, and chronic cough 
that persisted for over 2 weeks was the main cause (20-37.2%), 
although death and hospitalization from pertussis continue to 
occur predominantly in unvaccinated infants aged less than 6 
months
9, 10). 
In Korea, the incidence of pertussis has dramatically decreased 
since DTwP vaccination started in 1958 and DTwP was changed 
to DTaP in 1982. The number of pertussis cases reported to the 
KCDC was approximately 11.5 cases each year until 1991, but the 
incidence of pertussis seems to be on the rise since 2000, although 
the vaccination rate continues to be over 94%. In 2009, 66 cases 
of pertussis were reported. The KCDC confirmed that these cases 
were pertussis by culture or PCR of pertussis from nasal specimens 
and a positive rate of culture and PCR is very low compared 
to serologic study. On the basis of the sensitivity of the test and 
reporting rate in 2009, it can be assumed that more than 2,000 
pertussis occurred in 2009 (Fig. 1). 
Clinical manifestations and complications
Classical pertussis has 3 stages of clinical symptoms: catarrhal, 
paroxysmal, and convalescent. These stages are only seen in 
unimmunized toddlers and children. The 3 classical stages 
commence after 3-12 days of bacteria incubation. Nonspecific 
symptoms such as rhinorrhea, sneezing, mild fever, and eye 
infection without significant conjunctivitis occur after about 2 
weeks in the catarrhal stage, and these symptoms are followed 
by characteristic paroxysmal stage symptoms such as a dry, 
intermittent, irritative hack which evolves into paroxysms. In the 
paroxysmal stage, a healthy-looking, playful toddler suddenly 
begins to express an anxious aura and experiences bouts of 
uninterrupted coughing while drawing a single breath. The coughs 
are followed by a loud whoop as inspired air passes through the still 
partially closed glottis (Fig. 2).     
In infants younger than 3 months, the catarrhal phase usually 
lasts for a few days or is not recognized at all; the paroxysmal and 
convalescent stages are protracted, with periods of spasmodic 
coughing throughout the first year of life. In the paroxysmal stage, 
young infants frequently present with gagging, gasping, choking, 
cyanosis, apnea, or an “apparent life-threatening event” instead of 
paroxysmal coughing; whooping is absent.
In immunized children and adults, all stages of pertussis are 
shortened, and it is not uncommon for the disease to not have 
distinct stages and show chronic cough paroxysms that continue 
for more than 2 weeks. 
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infections such as pneumonia and otitis media; respiratory failure 
because of apnea, pneumonia, or pulmonary hypertension; and 
physical sequelae because of forceful coughing. Pertussis-related 
complications and mortality are reported, especially in patients 
younger than 2 months, who have the highest reported rates of 
pertussis-associated hospitalization (>90%), pneumonia (15-25%), 
seizures (2-4%), encephalopathy (0.5-1%), and death (0.5-1%)
11- 
13). There are several reports on pertussis as a significant cause of 
sudden infant death syndrom
14-16).
Diagnosis 
Pertussis should be considered as a diagnosis in very young 
infants who have not completed 3 doses of vaccination and have 
classical symptoms or in children who display major symptoms 
such as chronic paroxysmal cough without significant fever, 
general weakness, and sore throat and do not have physical signs 
such as wheezing and rales. Chlamydia trachomatis infection in 
very young infants and adenovirus, Mycoplasma pneumoniae, 
and Chlamydia pneumoniae infections should be the differential 
diagnosis for children because despite the abovementioned 
differences, it is not easy to diagnose pertussis on the basis of only 
clinical symptoms and signs, especially if secondary infections such 
as pneumonia are present.
The laboratory finding characteristic for pertussis is leukocytosis 
(leukocyte counts of 15,000-100,000 cells/mm
3) due to absolute 
lymphocytosis in the late catarrhal and paroxysmal stages. The 
degree of leukocytosis parallels the severity of illness and is mainly 
observed in unvaccinated children; leukocytosis is not common 
in adolescents, adults, and partially immunized children with 
pertussis
17, 18). Chest x-ray findings are normal in most cases, 
although chest x-ray images of hospitalized young infants may 
show hilar infiltration, interstitial edema, atelectasis, and, rarely, 
pneumothrax.
There are several ways to confirm B. pertussis infection such as 
serology, culture, direct fluorescent antibody (DFA) testing, and 
PCR. All these methods have limitations in terms of sensitivity, 
specificity, or practicality. 
The traditional gold standard for confirming pertussis is culture, 
but many factors that can influence the results, such as the stage 
of illness, use of antibiotics, cautious posterior nasopharyngeal 
sampling, adequate transport media (Regan-Lowe) and culture 
media (Regan-Lowe charcoal media with 10% horse blood or 
5-40 µg/mL cephalexin), and vaccination status of the patient. In 
adolescents and adults with pertussis, culture or PCR test results 
are positive in <10% of cases that have been confirmed as pertussis 
by serology. However, PCR is more rapid and sensitive than culture 
for confirming pertussis
19). 
Fig. 2. Manifestations and complications of pertussis. Abbreviations : DFA, direct fluorescent 
antibody; PCR, polymerase chain reaction. Adapted from Cherry JD, Brunell PA, Golden GS, 
et al. Report of the task force on pertussis and pertussis immunization-1988. Pediatrics 
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Serologic tests use enzyme immunoassay (EIA) to detect 
antibodies to components of B. pertussis and are the most sensitive 
tests for diagnosis in distantly immunized individuals and those 
evaluated after the second week of experiencing coughs. A 4-fold 
increase in anti-PT IgG with 4-6 week intervals appears to be the 
most reliable serologic test, and a single test showing an anti-PT 
IgG level of >94-110 EU/mL (over 2SD of the IgG level in the 
community) has been proposed as the diagnostic cutoff point
20).
Treatment  
The goals of therapy are to limit the number, severity, and 
duration of paroxysms and prevent complications. Hospitalization 
is usually needed to treat infants with pertussis because they need 
supportive care such as hydration, nutrition, and monitoring for 
complications.   
If the patient experienced uncontrolled severe cough along 
with hypoxia, seizures, and apnea, ventilator care should be 
provided along with muscle paralysis to prevent bradycardia and 
cardiopulmonary complications. 
Antibiotics should be given to infants younger than 1 year old 
who have had the cough paroxysm for less than 6 weeks and to 
all the patients who began coughing within 3 weeks in order to 
improve symptoms, shorten their duration, and prevent further 
infection
21). Erythromycin is the treatment of choice; 40-50 mg/
kg erythromycin is prescribed for 10-14 days. Newer macrolides 
such as clarithromycin and azithromycin can be used instead of 
erythromycin and have the same effect
22).
Isolation and prevention 
Since pertussis is extremely contagious, there have been many 
secondary cases and outbreaks of pertussis in hospitals and 
chronic-care facilities. To prevent infection from the index patient, 
droplet precautions are recommended for at least 5 days after 
the initiation of macrolide therapy and those who have had close 
exposure should get the same macrolide treatment as pertussis 
patients. In addition, children younger than 7 years who did not 
complete the 5 rounds of pertussis vaccination should complete the 
schedule of vaccination. Adolescents older than 11 years and adults 
should receive the Tdap (tetanus toxoid, diphtheria toxoid, acellular 
pertussis): booster vaccination.  
The most important and effective way to control pertussis 
is vaccination. The current pertussis vaccination schedule in 
Korea comprises a primary series of 3 vaccinations: the first 
dose is administered at 2 months of age, the second is a booster 
vaccination given at 18 months of age, and the third dose is also a 
booster vaccination given at 4-6 years of age.
Despite longstanding and widespread vaccination programs, 
pertussis remains endemic in many industrialized countries, 
including Australia, Canada, Italy, Japan, the Netherlands, 
Switzerland, and the United States, all of which have reported 
recent increases in incidence. Factors contributing to pertussis 
resurgence remain unclear, but possible causes are waning 
immunity, improved surveillance and diagnosis, and adaptation of 
circulating B. pertussis strains
23, 24). Although pertussis is classically 
a disease of infants and children, the main portions of the 
population showing an increased incidence of pertussis are adults 
and adolescents; these infected adolescents and adults become a 
source of infection for infants. Consequently, pertussis-related 
mortality increases
25).
To solve the problem of waning immunity after pertussis 
vaccination and disease, Tdap booster vaccination for adolescents 
older than 11 years and adults has been started since 2006 in the 
United States and was introduced in Korea in 2009.
Conclusion
Pertussis was a leading cause of death of children before pertussis 
vaccination was started, and the disease continues to be a leading 
cause of child mortality. The incidence and mortality of pertussis 
has been increasing since 1990 in developed countries despite 
these countries having vaccination rates of 95%.  After widespread 
vaccination, the diagnosis of pertussis is difficult because of lack 
of classical clinical manifestations in very young infants and 
vaccinated children. In Korea, the prevalence of pertussis might be 
increasing since 2000 and there was a pertussis outbreak in 2009. 
No epidemiological study based on serology has been done so far 
in Korea, and the exact number of pertussis cases that occur and 
are undiagnosed remains unknown. Therefore, we do not have any 
weapons to fight against future outbreaks of pertussis, a significant 
cause of mortality of very young infants. 
Therefore, I suggest that a nationwide epidemiologic study of 
pertussis be undertaken immediately. The study should aim to 
develop methods for serologic diagnosis, new devise vaccination 
strategies to prevent waning immunity and reduce the number of 
very young unvaccinated individuals, and develop diagnosis criteria 
for atypical pertussis.
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